SRR12475132
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.470
- G2M_CHECKPOINT+0.440
- MYC_TARGETS_V1+0.350
- PANCREAS_BETA_CELLS+0.260
- SPERMATOGENESIS+0.220
- PROTEIN_SECRETION+0.200
- ANDROGEN_RESPONSE+0.190
- MTORC1_SIGNALING+0.140
- MITOTIC_SPINDLE+0.090
- MYC_TARGETS_V2+0.090
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.440
- ALLOGRAFT_REJECTION-0.370
- IL6_JAK_STAT3_SIGNALING-0.340
- APOPTOSIS-0.330
- P53_PATHWAY-0.320
- INFLAMMATORY_RESPONSE-0.310
- MYOGENESIS-0.310
- INTERFERON_GAMMA_RESPONSE-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.280
- OXIDATIVE_PHOSPHORYLATION-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | de92b16c-4549-4025-9885-76c260c30cf7 | — | — | 0.867 |
| 2 | 680dcf75-8d74-45ca-b1d6-0ef7310e6473 | — | — | 0.859 |
| 3 | MDT-AP-0184 | Med | Medulloblastoma | 0.849 |
| 4 | SRR5088922 | — | — | 0.830 |
| 5 | SRR12202467 | — | — | 0.819 |
| 6 | BS_6NRTJSYK | Embryonal tumors | — | 0.817 |
| 7 | SRR33532819 | — | E | 0.816 |
| 8 | SJEPD031372_D1.RNA-Seq | EPN | Supratentorial EPN | 0.812 |
| 9 | SJEPD030795_D2.RNA-Seq | EPN | Posterior Fossa EPN | 0.807 |
| 10 | BS_ZV68CES9 | medulloblastoma | — | 0.797 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.140 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.090 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.090 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.090 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| PEROXISOME | 0.020 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.010 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |